drugset / Trial / NCT01305538

Crossover Post-herpetic Neuralgia (PHN)

NCT01305538

Phase 2 Completed 100 enrolled Bristol-Myers Squibb
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with post-herpetic neuralgia (PHN).

Timeline

Start
2011-03
Primary completion
2012-02
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-954561 Unknown 40 mg
Subject BMS-954561 Unknown 80 mg
Subject BMS-954561 Unknown 150 mg
Subject BMS-954561 Unknown 300 mg